Replimune Group, Inc.

As of June 30, 2026, Replimune Group, Inc. carries a market capitalization of 809.73M, placing it among publicly traded companies globally. Its enterprise value stands at 736.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Replimune Group, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Replimune Group, Inc. has 83.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Replimune Group, Inc. maintains a current ratio of 5.23, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 105.99, indicating elevated leverage, while an interest coverage ratio of -29.58 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Replimune Group, Inc. posted a negative return on equity (ROE) of -134.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -82.28, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 472.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Replimune Group, Inc. recorded an income tax benefit of -482,290.30 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -260.46M and -259.98M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Replimune Group, Inc.'s stock has gained approximately 49.58% over the past 52 weeks. The 50-day moving average sits at 11.88, while the 200-day moving average is 7.83.

Over the twelve months ended June 30, 2026, Replimune Group, Inc. generated - - in revenue and converted that into -259.98M in net income, yielding earnings per share of -2.86. EBITDA reached -257.64M, while operating income came in at -259.32M.

As of June 30, 2026, Replimune Group, Inc. holds 170.97M in cash and equivalents against 98.01M in total debt, resulting in a net debt position of -88.62M. Total book value stands at 92.47M, with working capital of 142.14M providing operational flexibility.

Replimune Group, Inc. produced -244.26M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.30M in capital expenditures, free cash flow totaled -245.56M - equivalent to -2.70 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -28.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.27, meaning Replimune Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Replimune Group, Inc. has an Altman Z-Score of -6.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.